CEFUROXIME

Cefuroxime Adverse Events Reported to the FDA Over Time

How are Cefuroxime adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Cefuroxime, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Cefuroxime is flagged as the suspect drug causing the adverse event.

Most Common Cefuroxime Adverse Events Reported to the FDA

What are the most common Cefuroxime adverse events reported to the FDA?

Vomiting	196 (1.94%)
Diarrhoea	169 (1.67%)
Anaphylactic Shock	156 (1.54%)
Dyspnoea	151 (1.49%)
Pruritus	142 (1.4%)
Rash	137 (1.35%)
Nausea	133 (1.31%)
Pyrexia	133 (1.31%)
Drug Ineffective	116 (1.15%)
Hypotension	107 (1.06%)
Erythema	104 (1.03%)
	Show More
Hypersensitivity	101 (1%)
Urticaria	95 (.94%)
Drug Interaction	82 (.81%)
Drug Hypersensitivity	74 (.73%)
Anaphylactic Reaction	71 (.7%)
Renal Failure Acute	69 (.68%)
Blood Pressure Decreased	68 (.67%)
Product Quality Issue	67 (.66%)
Abdominal Pain	63 (.62%)
Drug Exposure During Pregnancy	60 (.59%)
Loss Of Consciousness	60 (.59%)
Bronchospasm	59 (.58%)
Asthenia	57 (.56%)
Clostridium Difficile Colitis	57 (.56%)
Toxic Epidermal Necrolysis	53 (.52%)
Alanine Aminotransferase Increased	52 (.51%)
Dizziness	51 (.5%)
Malaise	51 (.5%)
Visual Acuity Reduced	51 (.5%)
Headache	50 (.49%)
Tachycardia	50 (.49%)
Pneumonia	47 (.46%)
Urinary Tract Infection	46 (.45%)
Chills	45 (.44%)
Cough	44 (.43%)
Fatigue	43 (.43%)
Abdominal Pain Upper	41 (.41%)
Blood Bilirubin Increased	41 (.41%)
Swelling Face	41 (.41%)
Jaundice	40 (.4%)
Oedema Peripheral	38 (.38%)
Rash Erythematous	38 (.38%)
Aspartate Aminotransferase Increase...	37 (.37%)
Dehydration	37 (.37%)
Face Oedema	37 (.37%)
General Physical Health Deteriorati...	37 (.37%)
Angioedema	36 (.36%)
Endophthalmitis	36 (.36%)
Rash Generalised	36 (.36%)
Convulsion	35 (.35%)
Dysgeusia	35 (.35%)
Hypertension	35 (.35%)
Circulatory Collapse	34 (.34%)
Syncope	34 (.34%)
Hyperhidrosis	33 (.33%)
Thrombocytopenia	33 (.33%)
Abortion Spontaneous	32 (.32%)
Flushing	32 (.32%)
Gamma-glutamyltransferase Increased	32 (.32%)
Blister	31 (.31%)
Dysphagia	31 (.31%)
Sepsis	31 (.31%)
Arthralgia	30 (.3%)
Multi-organ Failure	29 (.29%)
Pain	29 (.29%)
Pallor	29 (.29%)
Clostridial Infection	28 (.28%)
Blindness	27 (.27%)
Confusional State	26 (.26%)
Incorrect Route Of Drug Administrat...	26 (.26%)
Intraocular Pressure Increased	26 (.26%)
Oxygen Saturation Decreased	26 (.26%)
Parophthalmia	26 (.26%)
Wheezing	26 (.26%)
Back Pain	25 (.25%)
Choking	25 (.25%)
Conjunctival Oedema	25 (.25%)
Corneal Deposits	25 (.25%)
Cyanosis	25 (.25%)
Generalised Erythema	25 (.25%)
Lip Swelling	25 (.25%)
Sinusitis	25 (.25%)
Acute Respiratory Distress Syndrome	24 (.24%)
Condition Aggravated	24 (.24%)
Hepatic Failure	24 (.24%)
Oedema	24 (.24%)
Pharyngeal Oedema	24 (.24%)
Shock	24 (.24%)
Swollen Tongue	24 (.24%)
Blood Alkaline Phosphatase Increase...	23 (.23%)
Corneal Opacity	23 (.23%)
Hepatitis	23 (.23%)
Hypokalaemia	23 (.23%)
Leukocytoclastic Vasculitis	23 (.23%)
Swelling	23 (.23%)
Tremor	23 (.23%)
Anxiety	22 (.22%)
Chest Discomfort	22 (.22%)
Eosinophilia	22 (.22%)
Fall	22 (.22%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Cefuroxime, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cefuroxime is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Cefuroxime

What are the most common Cefuroxime adverse events reported to the FDA?

Epidermal And Dermal Conditions	891 (8.81%)
Gastrointestinal Signs	596 (5.89%)
Respiratory	445 (4.4%)
Allergic Conditions	436 (4.31%)
Infections - Pathogen Unspecified	366 (3.62%)
Neurological	366 (3.62%)
Therapeutic And Nontherapeutic Effe...	266 (2.63%)
Hepatic And Hepatobiliary	255 (2.52%)
Hepatobiliary	228 (2.25%)
Gastrointestinal Motility And Defec...	222 (2.19%)
Bacterial Infectious	219 (2.16%)
	Show More
Medication Errors	178 (1.76%)
Ocular Infections, Irritations And ...	175 (1.73%)
Cardiac And Vascular Investigations	172 (1.7%)
Decreased And Nonspecific Blood Pre...	171 (1.69%)
Cardiac Arrhythmias	148 (1.46%)
Body Temperature Conditions	141 (1.39%)
Angiedema And Urticaria	138 (1.36%)
Hematology Investigations	136 (1.34%)
Renal Disorders	127 (1.26%)
Oral Soft Tissue Conditions	125 (1.24%)
Vision	114 (1.13%)
Product Quality Issues	111 (1.1%)
White Blood Cell	110 (1.09%)
Bronchial Disorders	101 (1%)
Gastrointestinal Hemorrhages	84 (.83%)
Electrolyte And Fluid Balance Condi...	81 (.8%)
Injuries	77 (.76%)
Upper Respiratory Tract Disorders	75 (.74%)
Eye	74 (.73%)
Chemical Injury And Poisoning	73 (.72%)
Lower Respiratory Tract Disorders	71 (.7%)
Vascular	69 (.68%)
Skin Vascular Abnormalities	60 (.59%)
Anterior Eye Structural Change, Dep...	57 (.56%)
Coronary Artery	56 (.55%)
Muscle	56 (.55%)
Seizures	56 (.55%)
Headaches	55 (.54%)
Fungal Infectious	54 (.53%)
Joint	53 (.52%)
Physical Examination Topics	53 (.52%)
Procedural And Device Related Injur...	53 (.52%)
Renal And Urinary Tract Investigati...	53 (.52%)
Gastrointestinal Inflammatory Condi...	52 (.51%)
Musculoskeletal And Connective Tiss...	52 (.51%)
Skin Appendage Conditions	52 (.51%)
Anxiety Disorders	51 (.5%)
Cardiac Disorder Signs	49 (.48%)
Ocular Structural Change, Deposit A...	49 (.48%)
Metabolic, Nutritional And Blood Ga...	48 (.47%)
Deliria	47 (.46%)
Protein And Chemistry Analyses	47 (.46%)
Urinary Tract Signs	46 (.45%)
Movement Disorders	45 (.44%)
Abortions And Stillbirth	43 (.43%)
Enzyme	42 (.42%)
Tongue Conditions	42 (.42%)
Viral Infectious	42 (.42%)
Neurological, Special Senses And Ps...	38 (.38%)
Platelet	36 (.36%)
Therapeutic Procedures And Supporti...	36 (.36%)
Vascular Hypertensive	35 (.35%)
Anemias Nonhemolytic And Marrow Dep...	33 (.33%)
Nephropathies	32 (.32%)
Hemolyses And Related Conditions	31 (.31%)
Immunology And Allergy	30 (.3%)
Acid-base	25 (.25%)
Heart Failures	25 (.25%)
Retina, Choroid And Vitreous Hemorr...	25 (.25%)
Administration Site Reactions	22 (.22%)
Fatal Outcomes	22 (.22%)
Microbiology And Serology	22 (.22%)
Appetite And General Nutritional	21 (.21%)
Changes In Physical Activity	21 (.21%)
Spleen, Lymphatic And Reticulendoth...	21 (.21%)
Disturbances In Thinking	20 (.2%)
Embolism And Thrombosis	18 (.18%)
Inner Ear And Viiith Cranial Nerve	18 (.18%)
Peritoneal And Retroperitoneal Cond...	18 (.18%)
Salivary Gland Conditions	17 (.17%)
Gallbladder	16 (.16%)
Menstrual Cycle And Uterine Bleedin...	16 (.16%)
Vascular Inflammations	16 (.16%)
Water, Electrolyte And Mineral	16 (.16%)
Coagulopathies And Bleeding Diathes...	15 (.15%)
Exocrine Pancreas Conditions	15 (.15%)
Gastrointestinal Vascular Condition...	15 (.15%)
Lifestyle Issues	15 (.15%)
Personality Disorders	15 (.15%)
Pleural	15 (.15%)
Pregnancy, Labour, Delivery And Pos...	15 (.15%)
Blood And Lymphatic System Disorder...	14 (.14%)
Vascular Hemorrhagic	14 (.14%)
Arteriosclerosis, Stenosis, Vascula...	13 (.13%)
Central Nervous System Vascular	13 (.13%)
Obstetric And Gynecological Therape...	13 (.13%)
Suicidal And Self-injurious Behavio...	13 (.13%)
Vulvovaginal Disorders	12 (.12%)
Gastrointestinal Conditions	11 (.11%)
Gastrointestinal Stenosis And Obstr...	11 (.11%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Cefuroxime, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cefuroxime is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.